Literature DB >> 17703228

FcRn: the neonatal Fc receptor comes of age.

Derry C Roopenian1, Shreeram Akilesh.   

Abstract

The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus. In addition, throughout life, FcRn protects IgG from degradation, thereby explaining the long half-life of this class of antibody in the serum. In recent years, it has become clear that FcRn is expressed in various sites in adults, where its potential function is now beginning to emerge. In addition, recent studies have examined the interaction between FcRn and the Fc portion of IgG with the aim of either improving the serum half-life of therapeutic monoclonal antibodies or reducing the half-life of pathogenic antibodies. This Review summarizes these two areas of FcRn biology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703228     DOI: 10.1038/nri2155

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  733 in total

1.  Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.

Authors:  Roberta Fenoglio; Simone Baldovino; Savino Sciascia; Emanuele De Simone; Giulio Del Vecchio; Michela Ferro; Giacomo Quattrocchio; Carla Naretto; Dario Roccatello
Journal:  J Nephrol       Date:  2020-06-27       Impact factor: 3.902

2.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

3.  Maternal antibody persistence: a neglected life-history trait with implications from albatross conservation to comparative immunology.

Authors:  R Garnier; R Ramos; V Staszewski; T Militão; E Lobato; J González-Solís; T Boulinier
Journal:  Proc Biol Sci       Date:  2011-12-21       Impact factor: 5.349

Review 4.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 5.  Enterocytes: active cells in tolerance to food and microbial antigens in the gut.

Authors:  N Miron; V Cristea
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

6.  Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Jirong Lu; Victor J Wroblewski
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

7.  Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.

Authors:  Jian-Ming Gu; Xiao-Yan Zhao; Thomas Schwarz; Joachim Schuhmacher; Andreas Baumann; Elena Ho; Babu Subramanyan; Kathy Tran; Timothy Myles; Chandra Patel; Maria Koellnberger
Journal:  AAPS J       Date:  2017-05-17       Impact factor: 4.009

8.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

9.  Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery.

Authors:  Eric M Pridgen; Frank Alexis; Timothy T Kuo; Etgar Levy-Nissenbaum; Rohit Karnik; Richard S Blumberg; Robert Langer; Omid C Farokhzad
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

Review 10.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.